Booklet updates: Leukemia

The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published. 

 

Acute Lymphoblastic Leukemia (ALL) in Adults

Acute Lymphoblastic Leukemia (ALL) in Children and Teens

 The ALL Guide: Information for Patients and Caregivers

  • In November 2024, the Food and Drug Administration (FDA) approved revumenib (Revuforj®) for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
  • In November 2024, the Food and Drug Administration (FDA) approved obecabtagene autoleucel (Aucatzyl®) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
  • In June 2024, the Food and Drug Administration (FDA) expanded the indication of blinatumomab (Blincyto®) to include the treatment of adult and pediatric patients one month and older with:
    • CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.  
    • Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).  
    • CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.
  • As of June 2024, Erwinaze® (asparaginase erwinia chrysanthemi) has been discontinued. Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) is available as a treatment option.

 

Acute Myeloid Leukemia (AML) in Adults: In Detail

Acute Myeloid Leukemia in Children and Teens: In Detail

AML: The Basics

  • In May 2026, the Food and Drug Administration (FDA) approved decitabine and cedazuridine (Inqovi®) in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
  • In November 2025, the Food and Drug Administration (FDA) approved ziftomenib (Komzifti™) to treat adults with acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation whose AML has come back or did not improve after previous treatment(s) and who have no other satisfactory treatment options.
  • In November 2025, the Food and Drug Administration (FDA) expanded the indication of Revumenib (Revuforj®) to include the treatment of adults and children 1 year and older with acute myeloid leukemia with a nucleophosmin 1 (NPM1) mutation whose disease has come back or has not improved after previous treatment(s) and who have no other satisfactory treatment options.

 

Chronic Lymphocytic Leukemia: In Detail​ 

CLL: The Basics

No Updates

 

Chronic Myeloid Leukemia: In Detail​ 

CML: The Basics

No Updates

 

<< Previous Page

 


 

Blood Cancer United resources

Find free, specialized guidance and information for every type of blood cancer, request financial support, find emotional support, and connect with other members of the blood cancer community.

Patient Resources

Caregiver Resources

Health Care Professional Resources

Financial Support

Newsroom

Blogs

Our Patient Community

Blood Cancer United Registry

Other Helpful Organizations

We are Blood Cancer United.

Everyone affected by blood cancer—patients, survivors, caregivers, researchers, advocates, fundraisers, everyone—has a story. Share yours.
A young child celebrating the end of blood cancer treatment stands indoors ringing a brass “Ringing Out” bell mounted on a plaque. The child smiles with eyes closed, surrounded by red‑and‑white decorations and signs. They wear a black shirt that reads “My Last Day of Chemo — It Was Tough but I Was Tougher,” symbolizing strength, remission, and completion of chemotherapy

Loxley

B-cell acute lymphoblastic leukemia (ALL)

Snapshot of Tracy wearing a hat and glasses in front of a waterfall, a cancer survivor

Tracy

Acute myeloid leukemia (AML)

Young child with a shaved head stands outdoors on a sunlit driveway, raising both arms overhead while holding a small object, with a rural landscape and trailer in the background—an empowering moment symbolizing strength and resilience in the blood cancer community.

Oakley

acute lymphoblastic leukemia (ALL)

Gabriele Papa, AML

Gabriele

acute myeloid leukemia (AML)

Gerardo (Jerry), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) patient

Gerardo (Jerry)

myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) - In memory

A child is sitting cross-legged on a paved surface outdoors, wearing a white long-sleeve shirt under a blue sleeveless jumpsuit with large buttons on the front. The child has short, light-colored hair and is wearing brown sandals. In the background, there is a white picket fence and a blurred house. The lighting suggests a bright, sunny day.

Aero

B-cell acute lymphoblastic leukemia (B-ALL)

Individual wearing a head covering, face mask, and floral lei stands in a hospital or clinic setting holding a young child while raising a small mallet beside a ceremonial gong. Behind them, a window display reads “CANCER BE GONE” with photos and the phrase “GOOD VIBES FOUND HERE,” symbolizing a milestone moment of strength, healing, and support within a blood cancer care journey.

Shelby

acute lymphoblastic leukemia (ALL)

Two individuals stand outdoors on a grassy area near trees and a building, posing side by side. One individual wears a white textured dress and carries a green shoulder bag, while the other wears a light-colored outfit with a white coat and holds a bouquet of pink flowers tied with a ribbon. Natural greenery and a walkway are visible in the background, suggesting a celebratory or milestone moment.

Liz

acute myeloid leukemia (AML)

Individual wearing a navy quarter-zip with a visible ID badge stands beside a bookshelf in a bright indoor school library or community space, with glass doors and a red “EXIT” sign in the background, conveying a calm, supportive environment for learning and connection related to blood cancer awareness and community care.

Michael

acute myeloid leukemia (AML)

A person is standing outdoors in front of dense green foliage, wearing a black T-shirt with bold white text that reads “MEGA LAB” above a stylized skull graphic. The image is well-lit with natural light, and the background consists of leafy trees or bushes.

John

chronic myeloid leukemia (CML)

Scholarship Guide

Louis

chronic myelogenous leukemia (CML)

Here is descriptive, SEO‑driven alt text that includes **blood cancer**, stays objective, and avoids assumptions: **Alt text:** Two people posing for a close-up outdoor selfie at night near a brightly lit holiday tree in an urban plaza, with illuminated buildings in the background; image commonly shared in personal storytelling connected to blood cancer awareness, caregiver support, and survivorship advocacy.

Lia

Family member and caregiver

Share your story

See all stories

The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United. Learn more.